Low dose lisuride in advanced Parkinson disease
Tóm tắt
Lisuride was investigated for therapeutic effects in 19 patients with advanced Parkinson disease, no longer satisfactorily responding to routine L-Dopa therapy. The patients were treated with oral Lisuride (0.6–2.5 mg/die) and L-Dopa. The follow-up was at least 6 months. We noted a significant improvement on the Webster Rating Scale at 1st, 3td and 6th months. Disability and on-off phenomen were reduced. Side effects were few. Lisuride is a valuable tool in this type of patient.
Tài liệu tham khảo
Birkmayer W., Riederer P.:Effects of Lisuride on motor functions, psychomotor activity and psychic behaviour in Parkinson Disease. In Lisuride and other Dopamine Agonists. Calne DB et al, Raven Press, New York, pp. 453–461, 1983.
Canter C.J., De La Torre R., Nier M.:A method of evaluating disability in patients with Parkinson Disease. J. Nerve Mental Dis. 183: 146–147, 1961.
Colton T.:Statistica in medicina. Piccin Editore, pp. 221–223, 1979.
Cote T.E., Esekay R.L., Frey E.A. et al.:Actions of Lisuride on Adrenoreceptors and Dopamine receptors. In Lisuride and other Dopamine agonists. Calne DB et al, Raven Press, New York, pp. 45–33, 1983.
Duvoisin R.C.:The evaluation of extrapyramidal disease. In Monoamine, noyaux gris centraux et syndroxe de Parkinson. Ajuriaggera J, Masson, Paris, pp. 313–325, 1970.
Folstein M.F., Folstein S.E., Mc Hugh P.R.:Mini-mental State: a practical method for grading cognitive state of patients for the clinician. J. Psychiatr. Res. 12:189, 198, 1975.
Frattola L., Albizzati M.G., Bassi S., Ferrarese C., Trabucchi M.:On-off phenomena, dyskinesias and dystonias. Acta Neurol Scand. 66:227–236, 1982.
Hoehn M.M., Yahr M.D.:Parkinsonism: onset, progression and mortality. Neurology 17: 427–442, 1969.
Horowski R.:Differences in the dopaminergic effects of the Ergot Derivatives-Bromocriptine, Lisuride and D-LSD as compared with Apomorfine. Eur. J. Pharmacol. 51:157–166, 1978.
Lieberman A.N., Goldstein M., Neophytides A et al..Lisuride in Parkinson Disease: efficacy of Lisuride compared to L-Dopa. Neurology 31:961–965, 1981.
Lieberman A.N., Goldstein M., Leibowitz M. et al:Lisuride combined with L-Dopa in advanced Parkinson Disease. Neurology 31:1466/1469, 1981.
Kebahian J.W., Calne D.B.:Multiple receptors for Dopamine. Nature 277:93–96, 1979.
Marson C.D.:Success and problems on Long term L-Dopa therapin Parkinson Disease Lancet i, 346–349, 1977.
Meneghetti G., Bbracco F., Giometto B., Ferla S., Schernia E.:Therapeutic effect of Lisuride in advanced Parkinson's Disease. Eur. Neurol. 25: 74–80, 1986.
Obeso J.A., Lunquin M.R., Martinez-Lage J.M.:Lisuride infusion for Parkinson Disease. Ann. Neurol. 14: 134, 1983.
Obeso J.A., Lunquin M.R., Martinez-Lage Y.M.:Intravenous Lisuride corrects oscillations of motor performace in Parkinson Disease. Ann. Neurol. 19:31–35, 1986.
Obeso J.A.:Continous dopaminergic stimulation: Lisuride infusion. In Atti del IV European workshop on clinical neuropharmacology. Pamplona, Spagna, pp. 38, 1986.
Parkes J.D., Schahter M., Marsden C.D., Smith B., Wilson A.:Lisuride in Parkinsonism. Ann. Neurol. 9:48–52, 1981.
Rinne U.K.:New Ergot Derivatives in treatment of Parkinson's Disease. in Lisuride and Other Dopamine Agonists. Calne D.B. et al, Raven Press, New York, pp. 431–442, 1983.
Wabster D.D.:Critical analysis of the disability of Parkinson Disease. Mod. Treat. 5: 257–287, 1968.